RxDoctor Payments Data

Yohmarie Cajigas, MD

Family Medicine · Houston, TXNPI 1811972862

Payments from drug & device makers

$301in general payments, 2019–2025

Across 15 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$55
  • Abbott$49
  • Exact Sciences$30
  • Pfizer$29
  • Calliditas Therapeutics US Inc.$25
  • Phadia US Inc.$24
  • plus $90 from 5 others

What the payments were for

  • Food & beverage$301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$301 in reported general payments places this provider in the 40th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$19,721
Medicare patients
104
Services billed
249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$80,179
FarxigaDapagliflozin Propanediol25$27,789
EliquisApixaban23$27,511
TrulicityDulaglutide13$15,689
MyrbetriqMirabegron23$13,195
JardianceEmpagliflozin12$13,089
XareltoRivaroxaban11$11,647
Tresiba Flextouch U-100Insulin Degludec13$11,347
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,024
VascepaIcosapent Ethyl13$8,852
Breo ElliptaFluticasone/Vilanterol12$5,826
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$4,822
Atorvastatin Calcium296$2,358
Ezetimibe114$2,326
Insulin Lispro Kwikpen U-100Insulin Lispro12$1,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$80,17950 claims
PfizerEliquis$29$27,51123 claims
GSKTrelegy Ellipta, Breo Ellipta$55$15,85025 claims
Lilly USA, LLCTrulicity$18$15,68913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →